Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (LUCD), a subsidiary of PAVmed Inc.
Reporting Period: Quarter ended June 30, 2024 (Q2 2024).
Business Overview: Lucid is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer (EAC) in patients with GERD. Its flagship product is the EsoGuard Esophageal DNA Test, performed on samples collected via the EsoCheck device. The company operates as a single segment and is currently in a pre-profitability stage, relying on financing to fund commercialization and R&D.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $976 | $1,977 | $159 | $605 |
| Cost of Revenue | $1,614 | $3,269 | $1,549 | $2,887 |
| Gross Profit (Loss) | $(638) | $(1,292) | $(1,390) | $(2,282) |
| Operating Loss | $(11,192) | $(21,983) | $(11,584) | $(25,900) |
| Net Loss (Common Stockholders) | $(11,005) | $(29,113) | $(11,381) | $(27,628) |
| Cash and Equivalents (End of Period) | $24,920 (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities | $(24,094) (YTD 2024) | $(14,057) (YTD 2023) | ||
| Debt (Senior Secured Convertible Note) | $11,200 (Fair Value, Current Liability) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly to $0.98 million in Q2 2024 from $0.16 million in Q2 2023, driven by higher volume of EsoGuard tests performed in the company's CLIA laboratory.
- Operating Expenses: Total operating expenses remained relatively flat year-over-year for the quarter ($12.2M vs $11.7M), though General and Administrative (G&A) expenses increased by $1.0M due to higher professional fees and an increased Management Services Agreement (MSA) fee with PAVmed. R&D expenses decreased by $0.5M due to reduced clinical trial activities.
- Debt Fair Value: The Senior Secured Convertible Note generated a non-cash gain of $0.6 million in Q2 2024 due to a decrease in fair value, compared to a gain of $0.3 million in the prior year quarter. This was partially offset by a $0.5 million debt extinguishment loss in Q2 2024 resulting from debt repayments settled in common stock.
- Equity Transactions: The company raised approximately $29.8 million in gross proceeds through Series B and Series B-1 Preferred Stock offerings in Q1 and Q2 2024. A $7.5 million "deemed dividend" was recorded in Q1 2024 related to the exchange of Series A/A-1 stock for Series B stock, impacting the YTD net loss attributable to common stockholders.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Continued operations depend on obtaining third-party reimbursement for EsoGuard, increasing direct contracting, and raising additional capital. The company expects to continue incurring losses and negative operating cash flows.
- Financing Activities: The company completed a $30 million preferred stock offering in Q2 2024. It maintains a Senior Secured Convertible Note (maturing March 2025) with principal repayments settled in stock. The company also has access to a committed equity facility and an ATM facility, though usage has been limited recently.
- NASDAQ Compliance: On June 21, 2024, the company received notice from Nasdaq that its stock price had been below the $1.00 minimum bid price requirement for 30 consecutive days. The company has 180 days (until December 18, 2024) to regain compliance.
- Regulatory Environment: The FDA's final rule on Laboratory Developed Tests (LDTs) does not immediately impact EsoGuard, as it was marketed prior to the cutoff date and is NYS CLEP-approved, allowing it to remain under enforcement discretion.
- Related Party Transactions: The MSA fee with parent company PAVmed was increased to $0.83 million/month in January 2024 and further increased to $1.05 million/month effective July 1, 2024. A significant portion of fees was settled via stock issuance in Q1 2024.
Key Facts for Investor Verification
- Going Concern Status: Verify the company's specific plan to secure additional funding or achieve profitability within the 12-month window to avoid insolvency risks.
- Reimbursement Progress: Monitor updates on third-party insurance reimbursement coverage for the EsoGuard test, which is cited as the primary driver for future revenue growth.
- NASDAQ Compliance: Track the stock price performance to ensure the company meets the $1.00 minimum bid price requirement by December 18, 2024, to avoid delisting.
- Debt Obligations: Review the terms of the Senior Secured Convertible Note, specifically the conversion mechanics and the requirement to maintain $5.0 million in available cash and a $30 million market cap.
- Preferred Stock Dilution: Assess the potential dilution from the Series B and B-1 Preferred Stock, which carry conversion rights and dividend features payable in common stock.